[Chemiluminescence measurement in AIDS, lymphadenopathy and hemophilia patients] NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Chemiluminescence measurement in AIDS, lymphadenopathy and hemophilia patients]

Z Hautkr. 1985 Aug 1;60(15):1214-23. Unique Identifier : AIDSLINE MED/86021082
Stohr L; Altmeyer P; Sessler MJ; Scharrer I; Helm EB; Holzmann H

Abstract: In order to reveal the activity of polymorphonuclear neutrophil leukocytes (PMNL) representing the first step of defence against infections, measurements of chemiluminescence (CL) were performed in patients suffering from acquired immune deficiency syndrome (AIDS), lymphadenopathy, or hemophilia. In comparison with healthy controls, AIDS patients revealed significant reduction (about 50 per cent) of phagocytic, i.e. CL activity of neutrophils, which had been induced by Zymosan. Only part of the patients suffering from lymphadenopathy answered with decreased granulocyte activity on the application of Zymosan. If concanavalin A was used as stimulant of metabolic activity of PMNL-independently of phagocytosis-again AIDS and some of the lymphadenopathy patients showed a markedly reduced neutrophil response. In conclusion it should be stated that there is some evidence for at least two defects of cellular immunity associated with AIDS and to some extent, with AIDS-endangered homosexuals suffering from lymphadenopathy: first the defect of PMNL to answer to concanavalin A with increased metabolic activity, and secondly the defect of PMNL to start phagocytosis induced by Zymosan with a subsequent release of oxygen radicals which are measurable as chemiluminescence. The appraisal of granulocyte activity by means of measurements of chemiluminescence might become an additional criterion for AIDS diagnostics.
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/*IMMUNOLOGY Acyclovir/THERAPEUTIC USE Anti-Infective Agents, Urinary/THERAPEUTIC USE Comparative Study Concanavalin A/PHARMACOLOGY Drug Combinations/THERAPEUTIC USE English Abstract Hemophilia/*IMMUNOLOGY Human Immunoglobulins/ANALYSIS Luminescence Luminol Lymphoproliferative Disorders/*IMMUNOLOGY Male Neutrophils/*IMMUNOLOGY *Phagocytosis Sulfamethoxazole/THERAPEUTIC USE T-Lymphocytes, Helper-Inducer/CYTOLOGY T-Lymphocytes, Suppressor-Effector/CYTOLOGY Trimethoprim/THERAPEUTIC USE Zymosan/PHARMACOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/drugtherapy/KWDimmunologyacyclovir/therapeuticuseanti-infectiveagents,urinary/therapeuticusecomparativestudyconcanavalina/pharmacologydrugcombinations/therapeuticuseenglishabstracthemophilia/KWDimmunologyhumanimmunoglobulins/analysisluminescenceluminollymphoproliferativedisorders/KWDimmunologymaleneutrophils/KWDimmunologyKWDphagocytosissulfamethoxazole/therapeuticuset-lymphocytes,helper-inducer/cytologyt-lymphocytes,suppressor-effector/cytologytrimethoprim/therapeuticusezymosan/pharmacologyjournalarticle
860130
M8610095

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .